Shares of Gland Pharma gained 3.35% to trade at Rs 1,959.40 in Wednesday's session, driven by high volume and unusual trading activity. This increase reflects a notable shift in investor interest, marking a substantial move from the previous close.
Financial Performance:
The financial performance of Gland Pharma reveals the following:
Consolidated Quarterly Figures (in Rs Crore):
| Heading | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 1,537.45 Crore | Rs 1,401.71 Crore | Rs 1,405.83 Crore | Rs 1,384.05 Crore | Rs 1,424.91 Crore |
| Net Profit | Rs 192.42 Crore | Rs 143.76 Crore | Rs 163.53 Crore | Rs 204.69 Crore | Rs 186.54 Crore |
| EPS | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 |
The revenue for the quarter ending March 2025 stood at Rs 1,424.91 Crore, while the net profit was Rs 186.54 Crore, and the EPS was 11.32.
Consolidated Yearly Figures (in Rs Crore):
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 3,462.88 Crore | Rs 4,400.71 Crore | Rs 3,624.60 Crore | Rs 5,664.72 Crore | Rs 5,616.50 Crore |
| Net Profit | Rs 996.96 Crore | Rs 1,211.66 Crore | Rs 781.04 Crore | Rs 772.46 Crore | Rs 698.53 Crore |
| EPS | 63.07 | 73.81 | 47.44 | 46.90 | 42.40 |
| BVPS | 360.86 | 435.64 | 483.23 | 529.65 | 555.40 |
| ROE | 16.88 | 16.92 | 9.81 | 8.85 | 7.63 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
The company's revenue for the year 2025 was Rs 5,616.50 Crore. The net profit was Rs 698.53 Crore and EPS was 42.40. The Debt to Equity ratio for the same period was 0.03.
Standalone Yearly Figures (in Rs Crore):
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Sales | Rs 3,462 Crore | Rs 4,400 Crore | Rs 3,616 Crore | Rs 4,167 Crore | Rs 4,116 Crore |
| Other Income | Rs 134 Crore | Rs 223 Crore | Rs 240 Crore | Rs 166 Crore | Rs 215 Crore |
| Total Income | Rs 3,597 Crore | Rs 4,624 Crore | Rs 3,856 Crore | Rs 4,334 Crore | Rs 4,331 Crore |
| Total Expenditure | Rs 2,259 Crore | Rs 3,000 Crore | Rs 2,801 Crore | Rs 2,920 Crore | Rs 2,842 Crore |
| EBIT | Rs 1,338 Crore | Rs 1,624 Crore | Rs 1,055 Crore | Rs 1,413 Crore | Rs 1,488 Crore |
| Interest | Rs 3 Crore | Rs 5 Crore | Rs 7 Crore | Rs 7 Crore | Rs 22 Crore |
| Tax | Rs 337 Crore | Rs 406 Crore | Rs 272 Crore | Rs 362 Crore | Rs 375 Crore |
| Net Profit | Rs 997 Crore | Rs 1,212 Crore | Rs 775 Crore | Rs 1,043 Crore | Rs 1,089 Crore |
The sales for the year ending March 2025 stood at Rs 4,116 Crore, while the net profit was Rs 1,089 Crore.
Standalone Quarterly Figures (in Rs Crore):
| Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Sales | Rs 1,174 Crore | Rs 1,012 Crore | Rs 1,062 Crore | Rs 1,010 Crore | Rs 1,030 Crore |
| Other Income | Rs 46 Crore | Rs 48 Crore | Rs 57 Crore | Rs 65 Crore | Rs 43 Crore |
| Total Income | Rs 1,221 Crore | Rs 1,060 Crore | Rs 1,120 Crore | Rs 1,075 Crore | Rs 1,074 Crore |
| Total Expenditure | Rs 784 Crore | Rs 759 Crore | Rs 740 Crore | Rs 663 Crore | Rs 679 Crore |
| EBIT | Rs 437 Crore | Rs 301 Crore | Rs 379 Crore | Rs 412 Crore | Rs 394 Crore |
| Interest | Rs 4 Crore | Rs 0 Crore | Rs 0 Crore | Rs 18 Crore | Rs 3 Crore |
| Tax | Rs 111 Crore | Rs 77 Crore | Rs 98 Crore | Rs 99 Crore | Rs 101 Crore |
| Net Profit | Rs 321 Crore | Rs 222 Crore | Rs 281 Crore | Rs 295 Crore | Rs 290 Crore |
The sales for the quarter ending March 2025 stood at Rs 1,030 Crore, while the net profit was Rs 290 Crore.
Key Financial Ratios:
| Ratio | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 63.07 | 73.84 | 47.12 | 63.35 | 66.15 |
| Diluted Eps (Rs.) | 62.99 | 73.67 | 47.11 | 63.35 | 66.15 |
| Book Value [Excl. Reval Reserve]/Share (Rs.) | 360.86 | 435.68 | 482.90 | 546.13 | 592.08 |
| Dividend/Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 18.00 |
| Face Value | 1 | 1 | 1 | 1 | 1 |
| Gross Profit Margin (%) | 41.49 | 39.41 | 34.81 | 37.80 | 40.27 |
| Operating Margin (%) | 38.64 | 36.90 | 30.75 | 33.91 | 36.16 |
| Net Profit Margin (%) | 28.79 | 27.54 | 21.45 | 25.03 | 26.47 |
| Return on Networth / Equity (%) | 16.88 | 16.93 | 9.75 | 11.59 | 11.17 |
| ROCE (%) | 22.36 | 22.39 | 13.82 | 15.48 | 15.03 |
| Return On Assets (%) | 15.34 | 15.47 | 8.84 | 10.93 | 10.45 |
| Current Ratio (X) | 10.00 | 10.04 | 9.43 | 11.04 | 11.01 |
| Quick Ratio (X) | 7.51 | 8.01 | 6.77 | 7.99 | 8.62 |
| Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratios (X) | 392.34 | 331.03 | 169.82 | 200.87 | 72.59 |
| Asset Turnover Ratio (%) | 53.30 | 0.61 | 0.44 | 0.46 | 0.41 |
| Inventory Turnover Ratio (X) | 2.72 | 1.66 | 1.10 | 1.14 | 1.26 |
| 3 Yr CAGR Sales (%) | 46.21 | 46.72 | 17.19 | 9.70 | -3.29 |
| 3 Yr CAGR Net Profit (%) | 76.21 | 63.78 | 0.19 | 2.30 | -5.18 |
| P/E (x) | 39.29 | 44.32 | 26.92 | 29.13 | 24.07 |
| P/B (x) | 6.87 | 7.50 | 2.63 | 3.37 | 2.69 |
| EV/EBITDA (x) | 26.12 | 29.19 | 13.61 | 18.24 | 14.36 |
| P/S (x) | 11.71 | 12.21 | 5.78 | 7.28 | 6.37 |
The company’s P/E ratio as of March 2025 stood at 24.07 and P/B ratio was 2.69.
Corporate Actions:
Gland Pharma announced a final dividend of Rs 18 per share (1800%) on May 20, 2025.
The stock is exhibiting very bullish sentiment, according to Moneycontrol analysis.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
